IP Library › Granted Patent US 12,410,258
Granted Patent B2
US 12,410,258 · App. 18/660,672 · Granted Sep 9, 2025

Antibodies capable of binding to OX40, variants thereof and uses thereof

Inventors: Kristel Kemper (Utrecht, NL); Maarten van der Kroef (Utrecht, NL); Dennis Verzijl (Utrecht, NL); Andrea Gorlani (Utrecht, NL); Pauline Linda de Goeje (Utrecht, NL); Lars Guelen (Utrecht, NL); David Satijn (Utrecht, NL); Esther C. W. Breij (Utrecht, NL); Ugur Sahin (Mainz, DE); Sina Fellermeier-Kopf (Mainz, DE); Maren Köhne (Mainz, DE)
Assignees: Ganmab A/S; BioNTech SE
C07K16/2878A61P35/00C07K16/4241A61K2039/505C07K2317/24C07K2317/31C07K2317/35C07K2317/52C07K2317/565C07K2317/75C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,258
App. No.
18/660,672
Granted
Sep 9, 2025
Kind
B2
Abstract

The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

Claims (25)

1. An antibody capable of binding to human OX40, wherein the antibody comprises a VH having the sequence as set forth in SEQ ID NO: 20 and a VL having the sequence as set forth in SEQ ID NO: 21.

2. The antibody of claim 1 , wherein the antibody comprises a human IgG1 Fc region is of the human IgG1mf, human IgG1ma, human IgG1mx or human IgG1mz allotype.

3. The antibody of claim 1 , wherein the antibody comprises a human IgG1 Fc region comprising the sequence set forth in SEQ ID NO: 3.

4. The antibody of claim 1 , wherein the antibody is bivalent.

5. The antibody of claim 1 , wherein the antibody is a monospecific, bispecific or multi-specific antibody.

6. The antibody of claim 1 , wherein the antibody is a full-length antibody.

7. The antibody of claim 1 , wherein the antibody has a heavy chain constant region (CH) comprising a sequence selected from the group consisting of SEQ ID NOs: 58, 59, 60, and 61.

8. The antibody of claim 7 , wherein the antibody has a CH comprising the sequence as set forth in SEQ ID NO: 58.

9. An antibody capable of binding to human OX40, wherein the antibody comprises a heavy chain (HC) as set forth in SEQ ID NO: 18 and a light chain (LC) as set forth in SEQ ID NO: 19.

10. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

11. A kit-of-parts comprising the antibody of claim 1 and instructions for use of said kit.

12. The antibody of claim 9 , wherein the antibody is bivalent.

13. The antibody of claim 9 , wherein the antibody is a monospecific, bispecific or multi-specific antibody.

14. The antibody of claim 9 , wherein the antibody is a full-length antibody.

15. A pharmaceutical composition comprising the antibody of claim 9 and a pharmaceutically acceptable carrier.

16. A kit-of-parts comprising the antibody of claim 9 and instructions for use of said kit.

17. An antibody capable of binding to human OX40, wherein said antibody comprises:

a) a VH having the sequence as set forth in SEQ ID NO: 20 and a VL having the sequence as set forth in SEQ ID NO: 21

b) a human IgG1 Fc region comprising a P329R mutation and an E345R mutation, wherein the amino acid positions are numbered according to Eu numbering.

18. The antibody of claim 17 , wherein the Fc region is of the human IgG1mf, human IgG1ma, human IgG1mx or human IgG1mz allotype.

19. The antibody of claim 17 , wherein the antibody is bivalent.

20. The antibody of claim 17 , wherein the antibody is a monospecific, bispecific or multi-specific antibody.

21. The antibody of claim 17 , wherein the antibody is a full-length antibody.

22. A pharmaceutical composition comprising the antibody of claim 17 and a pharmaceutically acceptable carrier.

23. A kit-of-parts comprising the antibody of claim 17 and instructions for use of said kit.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2025
From: BREIJ, ESTHER C. W.; GORLANI, ANDREA; GUELEN, LARS; KEMPER, KRISTEL; SATIJN, DAVID; VERZIJL, DENNIS; DE GOEJE, PAULINE LINDA; VAN DER KROEF, MAARTEN
To: GENMAB A/S
Reel/Frame 071626/0966 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2025
From: FELLERMEIER-KOPF, SINA; KÖHNE, MAREN; SAHIN, UGUR
To: BIONTECH SE
Reel/Frame 071627/0033 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2025
From: FELLERMEIER-KOPF, SINA; KÖHNE, MAREN; SAHIN, UGUR
To: BIONTECH SE
Reel/Frame 071627/0071 →
Priority Claims (2)
EP 23173143 · May 12, 2023 · regional
EP 23213531 · Nov 30, 2023 · regional
Continuity (1)
Related Publication 20240376221A1 · Nov 14, 2024
References Cited (208)
US 5589466A · Felgner et al. · 1996 [cited by applicant]
US 5973972A · Kwon et al. · 1999 [cited by applicant]
US 6077835A · Hanson et al. · 2000 [cited by applicant]
US 6602684B1 · Umana et al. · 2003 [cited by applicant]
US 6808710B1 · Wood et al. · 2004 [cited by applicant]
US 7262028B2 · Van Berkel et al. · 2007 [cited by applicant]
US 7488802B2 · Collins et al. · 2009 [cited by applicant]
US 7612181B2 · Wu et al. · 2009 [cited by applicant]
US 7951918B2 · Glaser et al. · 2011 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8168757B2 · Finnefrock et al. · 2012 [cited by applicant]
US 8354509B2 · Carven et al. · 2013 [cited by applicant]
US 8735553B1 · Li et al. · 2014 [cited by applicant]
US 8779105B2 · Korman et al. · 2014 [cited by applicant]
US 9006399B2 · Liu et al. · 2015 [cited by applicant]
US 9221891B2 · Bancel et al. · 2015 [cited by applicant]
US 9254311B2 · Bancel et al. · 2016 [cited by applicant]
US 9834606B2 · Li et al. · 2017 [cited by applicant]
US 10195156B2 · Benenato et al. · 2019 [cited by applicant]
US 10259882B2 · Van Dijk et al. · 2019 [cited by applicant]
US 10449233B2 · Schreiber et al. · 2019 [cited by applicant]
US 20030115614A1 · Kanda et al. · 2003 [cited by applicant]
US 20100155133A1 · Makwinski et al. · 2010 [cited by applicant]
US 20100226923A1 · Rao et al. · 2010 [cited by applicant]
US 20140348839A1 · Chowdhury et al. · 2014 [cited by applicant]
US 20140377284A1 · Simons et al. · 2014 [cited by applicant]
US 20150079109A1 · Li et al. · 2015 [cited by applicant]
US 20150203579A1 · Papadopoulos et al. · 2015 [cited by applicant]
US 20160185840A1 · Hoerr et al. · 2016 [cited by applicant]
US 20160272708A1 · Chen · 2016 [cited by applicant]
US 20160376367A1 · Yuan et al. · 2016 [cited by applicant]
US 20170210806A1 · Liu · 2017 [cited by applicant]
US 20170334995A1 · Zettl et al. · 2017 [cited by applicant]
US 20180170866A1 · Payne et al. · 2018 [cited by applicant]
US 20180185482A1 · Sheng et al. · 2018 [cited by applicant]
US 20180222989A1 · Hoos et al. · 2018 [cited by applicant]
US 20190022247A1 · Ansell et al. · 2019 [cited by applicant]
US 20190276549A1 · De Jong et al. · 2019 [cited by applicant]
US 20210253725A1 · Sahin · 2021 [cited by examiner]
US 20230109496A1 · Ioan · 2023 [cited by examiner]
US 20230212291A1 · Jiang et al. · 2023 [cited by applicant]
US 20240400703A1 · Kemper · 2024 [cited by examiner]
CN 102250246A · 2011 [cited by applicant]
CN 107840887A · 2018 [cited by applicant]
EP 0629240A1 · 1994 [cited by applicant]
EP 1176195A1 · 2002 [cited by applicant]
EP 1870459A1 · 2007 [cited by applicant]
EP 2391343A2 · 2011 [cited by applicant]
EP 2972360A1 · 2016 [cited by applicant]
EP 3118224A1 · 2017 [cited by applicant]
EP 3174998A1 · 2017 [cited by applicant]
WO WO1992022653A1 · 1992 [cited by applicant]
WO WO1998050431A2 · 1998 [cited by applicant]
WO WO1999054342A1 · 1999 [cited by applicant]
WO WO2000046147A2 · 2000 [cited by applicant]
WO WO2000061739A1 · 2000 [cited by applicant]
WO WO2000070087A1 · 2000 [cited by applicant]
WO WO2001029246A1 · 2001 [cited by applicant]
WO WO2002020039A2 · 2002 [cited by applicant]
WO WO2002030954A1 · 2002 [cited by applicant]
WO WO2002031140A1 · 2002 [cited by applicant]
WO WO2003035835A2 · 2003 [cited by applicant]
WO WO2003042402A2 · 2003 [cited by applicant]
WO WO2003099196A2 · 2003 [cited by applicant]
WO WO2006121168A1 · 2006 [cited by applicant]
WO WO2006132670A2 · 2006 [cited by applicant]
WO WO2007059782A1 · 2007 [cited by applicant]
WO WO2007110205A2 · 2007 [cited by applicant]
WO WO2008003116A2 · 2008 [cited by applicant]
WO WO2008156712A1 · 2008 [cited by applicant]
WO WO2008157379A2 · 2008 [cited by applicant]
WO WO2009014708A2 · 2009 [cited by applicant]
WO WO2009079335A1 · 2009 [cited by applicant]
WO WO2009089004A1 · 2009 [cited by applicant]
WO WO2009101611A1 · 2009 [cited by applicant]
WO WO2009114335A2 · 2009 [cited by applicant]
WO WO2010026923A1 · 2010 [cited by applicant]
WO WO2010027827A2 · 2010 [cited by applicant]
WO WO2010036959A2 · 2010 [cited by applicant]
WO WO2010080538A1 · 2010 [cited by applicant]
WO WO2010089411A2 · 2010 [cited by applicant]
WO WO2010129304A2 · 2010 [cited by applicant]
WO WO2010151792A1 · 2010 [cited by applicant]
WO WO2011028952A1 · 2011 [cited by applicant]
WO WO2011066342A2 · 2011 [cited by applicant]
WO WO2011069104A2 · 2011 [cited by applicant]
WO WO2011082400A2 · 2011 [cited by applicant]
WO WO2011117329A1 · 2011 [cited by applicant]
WO WO2011131746A2 · 2011 [cited by applicant]
WO WO2011143545A1 · 2011 [cited by applicant]
WO WO2011159877A2 · 2011 [cited by applicant]
WO WO2011161699A2 · 2011 [cited by applicant]
WO WO2012023053A1 · 2012 [cited by applicant]
WO WO2012025525A1 · 2012 [cited by applicant]
WO WO2012025530A1 · 2012 [cited by applicant]
WO WO2012058768A1 · 2012 [cited by applicant]
WO WO2012075340A2 · 2012 [cited by examiner]
WO WO2012145493A1 · 2012 [cited by applicant]
WO WO2013004842A2 · 2013 [cited by applicant]
WO WO2013157953A1 · 2013 [cited by applicant]
WO WO2013173223A1 · 2013 [cited by applicant]
WO WO2013184218A1 · 2013 [cited by examiner]
WO WO2014031646A2 · 2014 [cited by applicant]
WO WO2014055648A1 · 2014 [cited by applicant]
WO WO2014108198A1 · 2014 [cited by applicant]
WO WO2014152774A1 · 2014 [cited by applicant]
WO WO2014179664A2 · 2014 [cited by applicant]
WO WO2014194302A2 · 2014 [cited by applicant]
WO WO2015035606A1 · 2015 [cited by applicant]
WO WO2015112800A1 · 2015 [cited by applicant]
WO WO2015112900A1 · 2015 [cited by applicant]
WO WO2016110584A1 · 2015 [cited by applicant]
WO WO2015158867A1 · 2015 [cited by applicant]
WO WO2016164480A1 · 2016 [cited by applicant]
WO WO2016200835A1 · 2016 [cited by applicant]
WO WO2017019805A1 · 2017 [cited by applicant]
WO WO2017019846A1 · 2017 [cited by applicant]
WO WO2017024465A1 · 2017 [cited by applicant]
WO WO2017025016A1 · 2017 [cited by applicant]
WO WO2017025051A1 · 2017 [cited by applicant]
WO WO2017040790A1 · 2017 [cited by applicant]
WO WO2017055547A1 · 2017 [cited by applicant]
WO WO2017071625A1 · 2017 [cited by applicant]
WO WO2017106656A1 · 2017 [cited by applicant]
WO WO2017093447A1 · 2017 [cited by examiner]
WO WO2017132825A1 · 2017 [cited by applicant]
WO WO2017133540A1 · 2017 [cited by applicant]
WO WO2017166804A1 · 2017 [cited by applicant]
WO WO2018006052A1 · 2018 [cited by applicant]
WO WO2018022831A1 · 2018 [cited by applicant]
WO WO2018031258A1 · 2018 [cited by applicant]
WO WO2018036472A1 · 2018 [cited by applicant]
WO WO2018083126A1 · 2018 [cited by applicant]
WO WO2018103017A1 · 2018 [cited by applicant]
WO WO2018103501A1 · 2018 [cited by applicant]
WO WO2018114877A1 · 2018 [cited by applicant]
WO WO2018114878A1 · 2018 [cited by applicant]
WO WO2018114879A1 · 2018 [cited by applicant]
WO WO2018146317A1 · 2018 [cited by applicant]
WO WO2018222711A2 · 2018 [cited by applicant]
WO WO2019000146A1 · 2019 [cited by applicant]
WO WO2019086497A2 · 2019 [cited by applicant]
WO WO2019223733A1 · 2019 [cited by applicant]
WO WO2020030570A1 · 2020 [cited by applicant]
WO WO2023031473A1 · 2023 [cited by applicant]
WO WO2023217987A1 · 2023 [cited by applicant]
Abdiche et al., “Antibodies Targeting Closely Adjacent or Minimally Overlapping Epitopes Can Displace One Another”, PLoS One, Jan. 6, 2017, 12(1): e0169535. [cited by applicant]
Barbas et al., “Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries”, J. Mol. Biol., Apr. 5, 1993, 230(3): 812-823. [cited by applicant]
Bebbington et al., “High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker”, Biotechnology, Feb. 1992, 10(2): 169-175. [cited by applicant]
Benvenisty et al., “Direct introduction of genes into rats and expression of the genes.”, PNAS USA, Dec. 1986, 83(24): 9551-9555. [cited by applicant]
Beurskens et al., “Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients”, J. Immunol., Apr. 1, 2012, 188(7): 3532-3541. Epub Feb. 24, 2012. [cited by applicant]
Bitter et al., “Expression and secretion vectors for yeast”, Methods in Enzymol., 1987, 153: 516-544. [cited by applicant]
Bleeker et al., “Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect”, Blood, Nov. 15, 2001, 98(10): 3136-314… [cited by applicant]
Brochet et al., “IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis”, Nucl. Acids Res., Jul. 1, 2008, 36: W503-508. [cited by applicant]
Choi et al., “T-cell agonists in cancer immunotherapy”, J. Immunother. Cancer, Oct. 5, 2020, 8(2): e000966. [cited by applicant]
Corsaro et al., “Enhancing the efficiency of DNA-mediated gene transfer in mammalian cells”, Somatic Cell Genetics, Sep. 1981, 7(5): 603-616. [cited by applicant]
Croft et al., “The significance of OX40 and OX40L to T-cell biology and immune disease”, Immunol. Rev., May 2009, 229(1): 173-191. [cited by applicant]
Davies et al., “Expression of GnTlll in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII”, Biotech… [cited by applicant]
De Jong et al., “A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of lgG Hexamers at the Cell Surface”, PLoS Biol. Jan. 6, 2016, 14(1): e1002344. [cited by applicant]
Dick et al., “C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes”, Biotechnol. Bioeng., Aug. 15, 2008, 100(6): 1132-1143. [cited by applicant]
Dimasi et al., “The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators”, J. Mol. Biol., Oct. 30, 2009, 393(3): 672-692. Epub Aug. 20, 2009. [cited by applicant]
Gutierrez et al., “OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors”, Clin. Cancer Res., Jan. 15, 2021, 27(2): 460-472. Epub Nov. 4, 2020. [cited by applicant]
Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains”, Nature, Jun. 3, 1993, 363(6428): 446-448. [cited by applicant]
He et al., “The emerging role of co-stimulatory molecules and their agonistic mAb-based combination therapies in melanoma”, Int. Immunopharmacol., Dec. 2020, 89(Pt B): 107097. Epub Oct. 19, 2020. [cited by applicant]
Laustsen et al., “Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis”, Arthritis Res Ther., Oct. 30, 2014, 16(5): 474. [cited by applicant]
Lefranc et al., “IMGT, the international ImMunoGeneTics database”, Nucleic Acids Research, Jan. 1, 1999, 27(1): 209-212. [cited by applicant]
Lindhofer et al., “Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies”, J. Immunol., Jul. 1, 1995, 155(1): 219-225. [cited by applicant]
Liu et al., “Heterogeneity of monoclonal antibodies”, J. Pharm. Sci., Jul. 2008, 97(7): 2426-2447. [cited by applicant]
Okazaki et al., “Fucose depletion from human lgG1 oligosaccharide enhances binding enthalpy and association rate between lgG1 and FcgammaRIIIa”, Mar. 5, 2004, J. Mol. Biol., 336(5): 1239-1249. [cited by applicant]
Patel et al., “In vivo delivery of synthetic human DNA-encoded monoclonal antibodies protect against ebolavirus infection in a mouse model”, Cell Reports, Nov. 13, 2018, 25(7): 1982-1993.e4. [cited by applicant]
Rice et al., “EMBOSS: The European Molecular Biology Open Software Suite”, Trends Genet., Jun. 2000, 16(6): 276-277. [cited by applicant]
Ruby et al., “OX40 Agonists can drive Treg expansion if the cytokine milieu is right”, J. Immunol., Sep. 28, 2009, 183(8): 4853-4857. [cited by applicant]
Schakowski et al., “A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA”, Mol. Ther., May 2001, 3(5 Pt. 1): 793-800. [cited by applicant]
Schlake et al., “mRNA: A Novel Avenue to Antibody Therapy?”, Mol Ther., Mar. 6, 2019, 27(4): 773-784. [cited by applicant]
Shen et al., “Single variable domain antibody as a versatile building block for the construction of lgG-like bispecific antibodies”, J. Immunol. Methods, Jan. 10, 2007, 318(1-2): 65-74. Epub Oct. 26, 2006. [cited by applicant]
Shields et al., “Lack of fucose on human lgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity”, J. Biol. Chem., Jul. 26, 2002, 277: 26733-26740. [cited by applicant]
Shinkawa et al., “The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human lgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cyt… [cited by applicant]
Sykes et al., “Linear expression elements: a rapid, in vivo, method to screen for gene functions”, Nat. Biotech., Apr. 1999, 17(4): 355-359. [cited by applicant]
Umana et al., “Engineered glycoforms of an antineuroblastoma lgG1 with optimized antibody-dependent cellular cytotoxic activity”, Nat. Biotech., Feb. 1999, 17(2): 176-180. [cited by applicant]
Van Heeke et al., “Expression of human asparagine synthetase in [cited by applicant]
Wigler et al., “Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor”, Cell, Jul. 1978, 14(3): 725-731. [cited by applicant]
Willoughby et al., “OX40: Structure and function—What questions remain?”, Mol. Immunol., Mar. 2017, 83: 13-22. Epub Jan. 13, 2017. [cited by applicant]
Zhang et al., “Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity”, Cell Rep., Jun. 11, 2019, 27(11): 3117-3123.e5. [cited by applicant]
Zhang et al., “Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody”, J. Biol. Chem., Dec. 30, 2016, 291(53): 27134-27146. Epub Nov. 17, 2016. [cited by applicant]
Ruby et al., “Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right”, J. Immunol., Oct. 15, 2009, 183(8): 4853-4857, Epublished Sep. 29, 2009. [cited by applicant]
U.S. Appl. No. 18/660,847, filed May 10, 2024, Kristel Kemper, Antibodies Capable of Binding to OX40, Variants Thereof and Uses Thereof. [cited by applicant]
U.S. Appl. No. 18/660,672 2024/0376221, filed May 10, 2024 Nov. 14, 2024, Kristel Kemper, Antibodies Capable of Binding to OX40, Variants Thereof and Uses Thereof. [cited by applicant]
U.S. Appl. No. 18/660,847 2024/0400703, filed May 10, 2024 Dec. 5, 2024, Kristel Kemper, Antibodies Capable of Binding to OX40, Variants Thereof and Uses Thereof. [cited by applicant]
Guo et al., PD-1 Blockade and OX40 triggering synergistically protects against tumor growth in a Murine Model of ovarian cancer, PLOS One, Feb. 2014, 9(2): e89350. [cited by applicant]
Calvo et al., Interim results of a phase 1/2 study of JNJ-63723283, an anti-PD-1 monoclonal antibody, in patients with advanced cancers., Journal of Clinical Oncology, 2018, 36 (Suppl. 5): Abstract 58. [cited by applicant]
Fu et al., Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity, Acta Pharmaceutica Sinica B, 2020, 10(3): 414-433. [cited by applicant]
Garber et al., Immune agonist antibodies face critical test, Nat. Rev. Drug Discov., Jan. 2020, 19(1): 3-5. [cited by applicant]
Hardy et al., A Monoclonal Antibody against a Human B Lymphoblastoid Cell Line Induces Tumor Regression in Mice, Cancer Research, Nov. 15, 1994, 54(22): 5793-5796. [cited by applicant]
Huang et al., Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma, Clinical Cancer Research, Mar. 15, 2018, 24(6): 1296-1304. [cited by applicant]
Ishida et al., Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, The EMBO Journal, 1992, 11(11): 3887-3895. [cited by applicant]
Johnson et al., Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors, Journal of Clinical Oncology, 2018, 36(5): Abstract 212. [cited by applicant]
Labrijn et al., Efficient generation of stable bispecific lgG1 by controlled Fab-arm exchange, PNAS, 2013, 110(13): 5145-5150. [cited by applicant]
Lao et al., OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer, Int Immunopharmacology, Jul. 2022, 108: 108813. [cited by applicant]
Li et al., A Mini-Review for Cancer Immunotherapy: Molecular Understanding of Pd-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints, Int J of Molecular Sciences, Jul. 18, 2016, 17: 1151. [cited by applicant]
Ma et al., Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer, Gastroenterology, 2020, 159: 306-319. [cited by applicant]
Naing et al., A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors, Journal of Clinical Oncology, 2016, 34 (Suppl 15): 3060 (Abstract 3060). [cited by applicant]
Needleman et al., A general method applicable to the search for similarities in the amino acid sequence of two proteins, J Mol Biol, Mar. 1970, 48(3): 443-453. [cited by applicant]
Sasikumar et al., Small-Molecule Immune Checkpoint Inhibitors Targeting PD1/PDL1 and Other Emerging Checkpoint Pathways, Bio Drugs, 2018, 32: 481-497. [cited by applicant]
Shaabani et al., A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018), Taylor & Francis, Sep. 2, 2018, 28(9): 665-678. [cited by applicant]
Taylor et al., Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay, Elsevier, Sep. 2001, 255(1-2): 67-72. [cited by applicant]
Youssef et al., Abstract 2667: In vitro properties and pre-clinical activity of PF-06801591, a high-affinity engineered anti-human PD-1, Cancer research, 2017, 33 (Suppl 13): 2667. [cited by applicant]
U.S. Appl. No. 19/062,470, filed Feb. 25, 2025, Kristel Kemper, Antibodies Capable of Binding to OX40, Variants Thereof and Uses Thereof. [cited by applicant]
U.S. Appl. No. 19/062,474, filed Feb. 25, 2025, Kristel Kemper, Antibodies Capable of Binding to OX40, Variants Thereof and Uses Thereof. [cited by applicant]